Abstract
Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Current Medicinal Chemistry
Title: New Trends in Thromboxane and Prostacyclin Modulators
Volume: 7 Issue: 6
Author(s): Jean -Michel Dogne, Xavier de Leval, Jacques Delarge, Jean -Louis David and Bernard initial Masereel
Affiliation:
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Abstract: Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Export Options
About this article
Cite this article as:
Dogne -Michel Jean, Leval de Xavier, Delarge Jacques, David -Louis Jean and Masereel initial Bernard, New Trends in Thromboxane and Prostacyclin Modulators, Current Medicinal Chemistry 2000; 7 (6) . https://dx.doi.org/10.2174/0929867003374868
DOI https://dx.doi.org/10.2174/0929867003374868 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Defective CD36 as a Quantitative Trait Locus for Cardiovascular Risk Factor Clustering in the Spontaneously Hypertensive Rat
Current Genomics Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Lycopene and Cardiovascular Diseases: An Update
Current Medicinal Chemistry Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews AMP-Activated Protein Kinase: Structure and Regulation
Current Protein & Peptide Science Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Role of Moving Average Analysis for Development of Multi-Target (Q)SAR Models
Mini-Reviews in Medicinal Chemistry Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations
Current Diabetes Reviews Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology